Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $15.6 million.

  • Immunome's Other Accumulated Expenses fell 13.74% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 13.74%. This contributed to the annual value of $24.2 million for FY2024, which is 1248.10% up from last year.
  • Per Immunome's latest filing, its Other Accumulated Expenses stood at $15.6 million for Q3 2025, which was up 47.63% from $10.6 million recorded in Q2 2025.
  • Immunome's Other Accumulated Expenses' 5-year high stood at $24.2 million during Q4 2024, with a 5-year trough of $713,000 in Q3 2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $10.6 million (2025), whereas its average is $9.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2,435.20% in 2024, then dropped by 26.95% in 2025.
  • Immunome's Other Accumulated Expenses (Quarterly) stood at $1.8 million in 2023, then soared by 1,248.10% to $24.2 million in 2024, then dropped by 13.74% to $15.6 million in 2025.
  • Its Other Accumulated Expenses was $15.6 million in Q3 2025, compared to $10.6 million in Q2 2025 and $12.5 million in Q1 2025.